How low do we fall to lower hemoglobin A1c? SGLT2 inhibitors: Effective drugs or expensive toxins!

Journals Menu

Follow SCIRP

ISSN Print: 2160-5831
ISSN Online: 2160-5858
www.scirp.org/journal/jdm
E-mail: jdm@scirp.org

Citations h5-index & Ranking*

"How low do we fall to lower hemoglobin A1c? SGLT2 inhibitors: Effective drugs or expensive toxins!"
written by Udaya M. Kabadi,
published by Journal of Diabetes Mellitus, Vol.3 No.4, 2013

has been cited by the following article(s):

[1]	SGLT2 Inhibitors: Far Too Many Cautions and Alerts and Limited Efficacy
	2018

[2]	Marked Weight Loss, Muscle Wasting and Fatigue on Administration of Empagliflozin in a Subject with Type 2 Diabetes
	British Journal of Medicine and Medical Research, 2017

[3]	Hyponatremia in the Emergency Department
	2016

[4]	Diabetic Ketoacidosis
	2016

[5]	New Oral Diabetes Drugs are more effective than Older Agents: Real or a Fraud
	2016

[6]	Sulfonylurea Glimepiride: A Proven Cost Effective, Safe and Reliable War Horse in Combating Hyperglycemia in Type 2 Diabetes
	Journal of Diabetes Mellitus, 2015

[1]	New Oral Diabetes Drugs are more effective than Older Agents: Real or a Fraud? Journal of Diabetes, Metabolic Disorders & Control, 2016 DOI:10.15406/jdmdc.2016.03.00071

[2]	SGLT2 Inhibitors: Far Too Many Cautions and Alerts and Limited Efficacy Journal of Diabetes, Metabolic Disorders & Control, 2016 DOI:10.15406/jdmdc.2016.03.00077

[3]	Sulfonylurea Glimepiride: A Proven Cost Effective, Safe and Reliable War Horse in Combating Hyperglycemia in Type 2 Diabetes Journal of Diabetes Mellitus, 2015 DOI:10.4236/jdm.2015.54026

Follow SCIRP

Free SCIRP Newsletters

Add your e-mail address to receive free newsletters from SCIRP.

Top